dc.contributor.author |
Marx, Wolfgang |
en |
dc.contributor.author |
McCarthy, Alexandra |
en |
dc.contributor.author |
Marshall, Skye |
en |
dc.contributor.author |
Crichton, Megan |
en |
dc.contributor.author |
Molassiotis, Alex |
en |
dc.contributor.author |
Ried, Karin |
en |
dc.contributor.author |
Bird, Robert |
en |
dc.contributor.author |
Lohning, Anna |
en |
dc.contributor.author |
Isenring, Elizabeth |
en |
dc.date.accessioned |
2018-12-09T21:26:54Z |
en |
dc.date.issued |
2020-02 |
en |
dc.identifier.issn |
1446-6368 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/44909 |
en |
dc.description.abstract |
AIM:There is significant recent interest in the role of ginger root (Zingiber officinale) as an adjuvant therapy for chemotherapy-induced nausea. The supplemental prophylactic intervention for chemotherapy-induced nausea and emesis (SPICE) trial aims to assess the efficacy by reduced incidence and severity of chemotherapy-induced nausea and vomiting, and enhanced quality of life, safety and cost effectiveness of a standardised adjuvant ginger root supplement in adults undergoing single-day moderate-to-highly emetogenic chemotherapy. METHODS:Multisite, double-blind, placebo-controlled randomised trial with two parallel arms and 1:1 allocation. The target sample size is n = 300. The intervention comprises four capsules of ginger root (totalling 60 mg of active gingerols/day), commencing the day of chemotherapy and continuing for five days during chemotherapy cycles 1 to 3. The primary outcome is chemotherapy-induced nausea-related quality of life. Secondary outcomes include nutrition status; anticipatory, acute and delayed nausea and vomiting; fatigue; depression and anxiety; global quality of life; health service use and costs; adverse events; and adherence. RESULTS:During the five-month recruitment period from October 2017 to April 2018 at site A only, a total of n = 33 participants (n = 18 female) have been enrolled in the SPICE trial. Recruitment is expected to commence at Site B in May 2018. CONCLUSIONS:The trial is designed to meet research gaps and could provide evidence to recommend specific dosing regimens as an adjuvant for chemotherapy-induced nausea and vomiting prevention and management. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
Nutrition & dietetics: the journal of the Dietitians Association of Australia |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Supplemental prophylactic intervention for chemotherapy-induced nausea and emesis (SPICE) trial: Protocol for a multicentre double-blind placebo-controlled randomised trial. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1111/1747-0080.12446 |
en |
pubs.issue |
1 |
en |
pubs.begin-page |
144 |
en |
pubs.volume |
77 |
en |
dc.rights.holder |
Copyright: The author |
en |
pubs.end-page |
150 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
751993 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Nursing |
en |
dc.identifier.eissn |
1747-0080 |
en |
pubs.record-created-at-source-date |
2018-07-24 |
en |
pubs.dimensions-id |
30033645 |
en |